# US 2011/0256093 A1 · Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256093 A1
- Document ID: US20110256093A1
- Status: Published application
- Kind: A1
- Application number: 13/087,502
- Filed: 2011-04-15
- Published: 2011-10-20
- Earliest claimed: 2010-04-16
- Assignees: National Cheng Kung University
- Inventors: Ming-Shi Chang
- Web page: https://patentgrep.com/patent/US20110256093A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A01K 67/0276: Knock-out vertebrates
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7155: {for interleukins [IL]}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/035: Animal model for multifactorial diseases
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

## Claims

### Claim 1

A method for treating a disorder associated with a signaling pathway mediated by an IL-20 receptor, comprising administering to a subject in need thereof an effective amount of an agent that suppresses the activity of the IL-20 receptor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disorder is osteoporosis, renal failure, diabetic nephropathy, rheumatoid arthritis, oral cancer, esophagus cancer, breast cancer, cancer-induced osteolysis, and ischemic stroke.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent is an antibody that binds to and neutralizes the IL-20 receptor, an antisense nucleic acid of the IL-20 receptor, a small molecule that inhibits the IL-20 receptor, or a dominant negative mutant of a cytokine that is IL-19, IL-20, or IL-24.

### Claim 4 (depends on 3)

The method of claim 3, wherein the disorder is osteoporosis, renal failure, or diabetic nephropathy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent is an antibody that binds to IL-20R1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody is a whole immunoglobulin molecule, an antigen-binding fragment thereof, a humanized antibody, a chimeric antibody, or an scFv.

### Claim 7 (depends on 5)

The method of claim 5, wherein the antibody is a bi-specific antibody that binds to both IL-20R1 and IL-19 or IL-20.

### Claim 8 (depends on 5)

The method of claim 5, wherein the antibody comprises (i) a heavy chain variable region containing the same complementarity determining regions (CDRs) as those in the heavy chain variable region of monoclonal antibody mAb7GW and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb7GW; or (ii) a heavy chain variable region containing the same CDRs as those in the heavy chain variable region of monoclonal antibody mAb51D and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb51D.

### Claim 9 (depends on 5)

The method of claim 5, wherein the antibody comprises (i) the heavy chain variable region and the light chain variable region of mAb7GW; or (ii) the heavy chain variable region and the light chain variable region of mAb51D.

### Claim 10 (depends on 5)

The method of claim 5, wherein the antibody is a humanized antibody of mAb7GW or mAb51D.

### Claim 11 (depends on 1)

The method of claim 1, wherein the agent is an antisense RNA targeting IL-20R1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the antisense RNA is an siRNA that silences expression of IL-20R1.

### Claim 13 (depends on 1)

The method of claim 1, wherein the disorder is osteoporosis.

### Claim 14 (depends on 13)

The method of claim 13, wherein the agent is an antibody that binds to IL-20R1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antibody is a whole immunoglobulin molecule, an antigen-binding fragment thereof, a humanized antibody, a chimeric antibody, or an scFv.

### Claim 16 (depends on 14)

The method of claim 14, wherein the antibody comprises (i) a heavy chain variable region containing the same complementarity determining regions (CDRs) as those in the heavy chain variable region of monoclonal antibody mAb7GW and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb7GW; or (ii) a heavy chain variable region containing the same CDRs as those in the heavy chain variable region of monoclonal antibody mAb51D and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb51D.

### Claim 17 (depends on 16)

The method of claim 16, wherein the antibody comprises (i) the heavy chain variable region and the light chain variable region of mAb7GW; or (ii) the heavy chain variable region and the light chain variable region of mAb51D.

### Claim 18 (depends on 14)

The method of claim 14, wherein the antibody is a humanized antibody of mAb7GW or mAb51D.

### Claim 19

An isolated antibody that binds to IL-20R1, wherein the antibody comprises (i) a heavy chain variable region containing the same complementarity determining regions (CDRs) as those in the heavy chain variable region of monoclonal antibody mAb7GW and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb7GW; or (ii) a heavy chain variable region containing the same CDRs as those in the heavy chain variable region of monoclonal antibody mAb51D and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb51D.

### Claim 20

(canceled)

### Claim 21 (depends on 20)

The isolated antibody of claim 20, wherein the antibody is mAb7GW or mAb51D, or an antigen-binding fragment thereof

### Claim at position 22

22-23. (canceled)
